Odds ratios were calculated by comparing cancer incidence (any cancer, multiple primary cancer, breast cancer, and bilateral breast cancer) among participants with a monoallelic PV in CHEK2 and those with PV and LR variant, and the differences were not statistically significant (Table). This evidence concerns the gene CHEK2 and breast cancer.